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TObjective: Approximately 50% of aortocoronary saphenous vein grafts are occluded
10 years after coronary revascularization surgery. Intimal hyperplasia, a critical
component in saphenous vein graft failure, is defined by vascular smooth muscle
cell proliferation, which is mediated in part by  subunits of heterotrimeric G
proteins (G) and downstream effectors such as mitogen-activated protein kinases.
A peptide consisting of the carboxyl-terminus of the -adrenergic receptor kinase
(ARKct) binds G, thereby inhibiting G signaling. Utilizing a recombinant
adenovirus containing the coding sequence for the ARKct peptide (AdARKct),
this study investigates whether treatment of the vein graft with AdARKct reduces
intimal hyperplasia in a large animal model of aortocoronary saphenous vein graft
intimal hyperplasia.
Methods: Twenty-seven dogs (27-32 kg) underwent aortocoronary bypass grafting
to the left anterior descending artery using autologous saphenous vein. Vein grafts
were treated with saline (n  8), an empty adenovirus (n  8), or AdARKct (n 
8). A subset of dogs (n  3) were sacrificed on postoperative day 7 and ARKct
expression confirmed by Northern blotting.
Results: Arteriograms performed on postoperative day 90 confirmed that saphenous
vein grafts were patent. At postoperative day 90, AdARKct-treated grafts dem-
onstrated reduced intimal area compared to empty virus and saline treated animals
(P  .05). Additionally, AdARKct treatment of isolated vascular smooth muscle
cells in vitro inhibited mitogen-activated protein kinase activation and decreased
overall vascular smooth muscle cell proliferation.
Conclusion: This study demonstrates that ARKct expression in aortocoronary
saphenous vein grafts reduces intimal hyperplasia and decreases vascular smooth
muscle cell proliferation in vitro via inhibition of G-mediated mitogen-activated
protein kinase activation. Modulation of G via ARKct may represent a novel
therapy to reduce intimal hyperplasia and saphenous vein graft failure.
Saphenous vein grafts (SVGs) remain the most common conduit used forsurgical revascularization procedures, including coronary artery bypass graft-ing (CABG). Unfortunately, aortocoronary grafting with SVGs is limited
because of intimal hyperplasia (IH) and subsequent vein graft atherosclerosis, which
leads to a 10-year failure rate of almost 50%.1,2 IH is a chronic structural lesion that
develops after vein graft implantation and leads to luminal stenosis and occlusion.
IH is defined as abnormal hypertrophy, proliferation, and migration of vascular
smooth muscle cells (VSMCs) from the tunica media to the intima, with associated
deposition of an extracellular connective tissue matrix.
Current approaches to limit SVG failure include technical considerations, long-
term aspirin therapy, and lipid-lowering medications.3,4 Despite these interventions,
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clinical problem, leading to recurrent angina and a 10% to
15% incidence of need for reoperative CABG.5
Although they have not been completely characterized,
molecular signaling mechanisms important in VSMC pro-
liferation have been studied in experimental models of
vessel injury. G proteins have been identified as important
mediators of this process, because many growth factors that
induce VSMC mitogenesis act through G protein–coupled
receptors.6 With ligand binding, G protein–coupled recep-
tors interact with heterotrimeric G proteins, triggering the
dissociation of the G protein into individual  and 
subunits. Specifically, G protein  subunits (G) have
been shown to trigger intracellular signaling events leading
to activation of p21ras (ras) and subsequent phosphorylation
of the p42 and p44 mitogen-activated protein (MAP) ki-
nases in VSMCs.7 Stimulation of the ras–MAP kinase path-
way is important for the induction of VSMC proliferation.
Specifically, extracellular signal–regulated receptor kinase
(ERK) is a member of the MAP kinase family that has been
previously implicated as a key mediator of VSMC growth,
proliferation, and survival.8
G subunits have also been shown to bind to the car-
boxyl terminus of the cytosolic enzyme -adrenergic recep-
tor kinase 1 (ARK1), enabling translocation of ARK1 to
the cell membrane, where the enzyme is responsible for
phosphorylation of activated receptors. This membrane-
targeting event is mediated through binding of the carboxyl
terminus of ARK1 with G.9 Previous studies have
shown that peptides consisting of the carboxyl-terminal
G-binding domain act as inhibitors of both in vitro and in
Abbreviations and Acronyms
Ad  adenovirus
AdGFP  adenoviruses containing the coding
sequence for the green fluorescent protein
ANOVA analysis of variance
ARK1  -adrenergic receptor kinase 1
CABG  coronary artery bypass grafting
DNA  deoxyribonucleic acid
EGF  epidermal growth factor
ERK  extracellular signal–regulated receptor
kinase
EV  empty virus
FBS  fetal bovine serum
IH  intimal hyperplasia
LPA  lysophosphatidic acid
MAP mitogen-activated protein
POD  postoperative day
SVC  saphenous vein graft
VMSC  vascular smooth muscle cellvivo G-dependent processes.7 A peptide known as
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of ARK1, acts as a competitive inhibitor of G-mediated
processes. In vivo delivery of ARKct has been accom-
plished with a replication-deficient recombinant adenoviral
vector containing the coding sequence for ARKct
(AdARKct). Previous investigations by our laboratory
have demonstrated that AdARKct inhibits VSMC prolif-
eration in vitro and in a small-animal model of arterial
injury.6
The effectiveness of the AdARKct in inhibiting aorto-
coronary SVG IH has not yet been examined in a clinically
relevant large-animal model. This study was designed to
provide preclinical data that could support the clinical ap-
plication of AdARKct as a treatment for SVG IH. Previ-
ously, we characterized a canine model of aortocoronary
SVG IH and demonstrated efficient transgene expression in
the SVG vessel wall after an ex vivo treatment with adeno-
viral vectors.10 This study tests the hypothesis that ARKct
could reduce aortocoronary SVG IH in this large-animal
model of aortocoronary SVG IH. In addition, the effects of
ARKct expression in cultured canine saphenous vein
smooth muscle cells were investigated.
Methods
Experimental Design
Animals used in this study were mongrel dogs (n  27, 27-32 kg).
Each animal underwent CABG with a reversed SVG from the
aorta to the left anterior descending coronary artery as previously
described.10 Before grafting, veins were treated with 1 1012 total
virus particles of either AdARKct (n  8) or empty virus (EV,
n  8). A third group of animals did not have their vein grafts
treated with any adenoviral vector and served as a negative control
group (control, n  8). Graft blood flow was confirmed by ultra-
sonic probe (Transonic Systems, Inc, Ithaca, NY) immediately
after completion of the distal anastomosis. SVG patency was
confirmed by an arteriogram performed on postoperative day
(POD) 90. On POD 90, dogs were sacrificed and their SVGs
explanted, sectioned, and stained with hematoxylin and eosin.
SVG intimal and medial areas were calculated with Image Tool
v.3.0 (The University of Texas Health Sciences Center, San An-
tonio, Tex). A separate subset of animals treated with AdARKct
(n  3) were sacrificed on POD 7 to assess graft and systemic
transgene expression.
One animal from the control group died of a fatal arrhythmia
immediately after the operation. One animal from the EV group
died of hemorrhage on POD 2. Accordingly, 22 dogs completed
the full 90-day protocol. Animal care complied with Duke Uni-
versity Medical Center animal care and use guidelines, the “Prin-
ciples of Laboratory Animal Care” of the National Society for
Medical Research, and the “Guide for the Care and Use of Labo-
ratory Animals” (http://www.nap.edu/catalog/5140.html).
Adenovirus Construction
The structure of a recombinant, replication-deficient adenovirus
directing the expression of ARKct (AdARKct) has been de-
scribed previously.11 The adenoviral backbone for the vectors is a
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with deletions of E1 and E4.11 These gene deletions render the
adenovirus unable to replicate. The complementary DNA for
ARKct was cloned into this vector, generating the vector
AdARKct. Control viruses were also constructed, including an
empty adenovirus containing no complementary DNA insert (EV)
and adenoviruses containing the coding sequence for the green
fluorescent protein (AdGFP).
Operative Protocol
Saphenous vein harvest, SVG gene delivery, and CABG were
performed as previously described.10 In brief, each animal was
sedated and intubated, and approximately 10 cm of SVG was
harvested from the left hind leg. An aliquot of 1  1012 total
virus particles was thawed and suspended in 2 mL phosphate-
buffered saline solution. This suspension was delivered intralu-
minally with a measured distention pressure of approximately
10 mm Hg for a 20-minute incubation period. After the treat-
ment, the SVG was submerged in 3% albumin. For the control
group, each SVG was gently flushed and submerged in 3%
albumin. A partial lower sternotomy was performed, a chest retractor
was placed, the pericardium was opened, intravenous heparin was
administered (50 U/kg), and a Satinsky clamp was placed to par-
tially occlude the ascending aorta. An aortotomy was created, and
an end-to-side running anastomosis was performed with 6-0 Pro-
lene (Ethicon, Inc, Somerville, NJ). A myocardial stabilizer was
positioned over the distal left anterior descending coronary artery,
a coronary arteriotomy was created, and an end-to-side running
anastomosis was performed with 7-0 Prolene. The proximal left
anterior descending coronary artery was ligated, rendering the
anterior left ventricle SVG dependent. An ultrasonic vascular
probe (Transonic Systems) confirmed flow through the SVG. All
grafts had blood flow greater than 30 mL/min. The sternum was
reapproximated, and the chest was closed in layers. Animals were
maintained with buffered aspirin (325 mg/d) throughout the study.
Tissue Preparation and Analysis
Animals were sacrificed with a lethal dose of intra-arterial Eu-
thosol (pentobarbital 390 mg/mL and phenytoin 50 mg/mL) on
either POD 7 or POD 90. SVG, liver, and lung specimens were
collected. The SVG was placed into 10% formalin for a minimum of
24 hours. Segments were embedded in paraffin and cut in cross-
section for histologic staining and measurements. Cross-sections
(5 m) were taken every 0.5 cm and prepared with a modified
hematoxylin and eosin stain. For animals at both POD 7 and POD
90, Northern analysis was also performed on lung, liver, non-
grafted saphenous vein, and SVG samples from AdARKct-
treated animals to assay for expression of ARKct as previously
described.12
Angiographic Confirmation of SVG Patency
On PODs 30 and 90, the dogs underwent coronary arteriography
through the femoral artery. A 6F coronary catheter was placed into
the left coronary artery under fluoroscopic guidance, and ra-
diopaque dye was used to confirm patency of the SVG.
The Journal of ThoracicMeasurement of SVG Wall Dimensions
All SVG vessel sections were digitally photographed at 5 mag-
nification. Photomicrographs demonstrating maximal IH from
each third of the SVG were analyzed. For each SVG section
analyzed, intimal area, medial area, maximal wall thickness, and
minimal wall thickness were determined by a blinded operator
with Image Tool v.3.0. For each SVG, mean values were calcu-
lated as previously described.12 The ratio between the intimal and
medial areas was calculated.
Cell Harvest and Culture
VSMCs were isolated from canine saphenous veins harvested
under sterile conditions. In brief, the adventitia was stripped away
and the intima removed by blunt dissection. The media was cut
into 1-cm2 sections and placed in culture dishes containing a
small amount of growth medium as previously described.13 After
10 days, veins were removed, and monolayers of smooth muscle
cells were trypsinized and passaged. In this study, only cells
between passages 3 and 5 were used.
Adenoviral Treatment
VSMCs were grown in 12-well plates in Dulbecco’s modified
Eagle’s medium and F12 Ham’s medium containing 10% fetal
bovine serum (FBS). When the cells were nearly confluent, the
medium was changed to 2% FBS, and viral vectors were added at
a multiplicity of infection of 100. After 24 hours, the medium was
changed to be serum free, followed by different treatments or
stimuli as indicated. As a control in all experiments, identical
groups of cells were left uninfected but incubated 24 hours in 2%
FBS.
Immunoblotting
After overnight infection with adenoviruses, VSMCs were serum
starved for 5 hours and then stimulated 5 minutes with lysophos-
phatidic acid (LPA, 10 mol/L), epidermal growth factor (EGF,
10 mol/L), or FBS (5%). Cells were lysed in Triton lysis buffer
(The Dow Chemical Company, Midland, Mich),14 and samples
were separated by sodium dodecylsulfate 8% to 16% polyacryl-
amide gel electrophoresis and transferred to nitrocellulose. Mem-
branes were Western blotted with the following antibodies: anti-
GRK2 polyclonal (SC-562, Santa Cruz Biotechnology, Inc, Santa
Cruz, Calif), anti–phospho-p44/42 ERK (Thr202/Tyr204; Cell
Signaling Technology, Inc, Beverly, Mass), anti–p44/42 ERK
(Cell Signaling Technology), and rat monoclonal anti–-tubulin
(clone YL1/2; Abcam Inc, Cambridge, Mass).
Thymidine Incorporation and Cell Counts
To evaluate the effect of ARKct expression on serum-mediated
DNA synthesis in VSMCs, tritiated thymidine incorporation was
assayed as previously described.14 In brief, VSMCs were plated in
triplicate in 12-well plates at a concentration of 20,000 cells/well.
The following day, the cells were either left uninfected or were
infected with AdARKct or AdGFP. The next day, cells remained
quiescent in serum-free medium for another 24 hours. The medium
was replaced with fresh serum-free medium with or without ago-
nists, and the cells were incubated 18 hours. The cells were pulse
labeled with tritiated thymidine (2 Ci/mL; Amersham Pharmacia
and Cardiovascular Surgery ● Volume 130, Number 6 1685
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ration was then assessed by liquid scintillation counting.
For cell counts, VSMCs were plated in triplicate on 12-well
plates and either left uninfected or infected with AdARKct or
AdGFP. The medium was changed to be serum free, and the cells
were incubated for 48 hours with or without agonists. The cells
were trypsinized and counted on a hemocytometer (Fisher Scien-
tific Worldwide, Hampton, NH).
Statistical Analysis
All data are presented as mean SEM. Statistical significance was
determined by the Student t test or 1-way analysis of variance
(ANOVA) where appropriate. After ANOVA, pairwise compari-
sons were then made with the Bonferroni or Student-Newman-
Keuls post hoc tests.
Results
Tissue Analysis
Northern analysis was performed on total RNA isolated
from lung, liver, nongrafted saphenous vein, and SVG from
AdARKct-treated dogs killed on POD 7 (n  3). The
ARKct messenger RNA was detected by Northern analysis in
all 3 SVG samples. Lung, liver, and nongrafted saphenous vein
RNA samples from the AdARKct-treated group did not dem-
onstrate any transgenic expression (Figure 1). Northern anal-
ysis was also performed on tissue samples from dogs treated
with AdARKct who were killed on POD 90 (n  8). As
expected, because of the transient nature of adenoviral vec-
tors, no appreciable ARKct transgene expression was ob-
served (data not shown).
Assessment of SVG Patency
All SVGs in this study (n  27) were patent after comple-
tion of the distal anastomosis, as documented with an ul-
trasonic vascular flow probe. Flow values for each animal
were at least 30 mL/min. Angiograms obtained on POD 90
demonstrated that the SVGs of all surviving animals were
Figure 1. Northern blot analysis of ARKct expression. RNA was
extracted from tissues harvested from animals killed on POD 7
whose SVGs had been treated with AdARKct (1  1012 total
virus particles). Northern blot analysis was performed with ra-
diolabeled ARKct probe. Lane 1, lung; lane 2, liver; lane 3,
nongrafted saphenous vein (NGSV); lane 4, AdARKct-treated
SVG.patent (n  22). Extensive filling defects consistent with
1686 The Journal of Thoracic and Cardiovascular Surgery ● Decgraft wall thickening were noted throughout the control and
EV-treated SVGs relative to the AdARKct treated SVGs.
(Figure 2, A and B).
Histologic Analysis
Histologic analysis is summarized in Table 1. SVG mean
intimal area was decreased by approximately 50% in the
AdARKct-treated groups relative to the control and EV
groups (1.32  0.44 mm2 vs 2.83  0.53 mm2 vs 2.41 
0.67 mm2, P  .05). Similar reductions in intima/media
ratio (0.59  0.16 vs 1.22  0.43 vs 1.47  0.41, P  .05)
and maximal wall thickness (1.14  0.31 mm vs 1.94 
0.90 mm vs 1.87  0.45 mm, P  .05) were noted in the
AdARKct-treated group relative to the control and EV
groups, respectively. No differences in medial thickness
were noted among the three groups (P .1). Representative
photomicrographs of SVGs from control and AdARKct-
treated animals are shown in Figure 2, C and D.
In Vitro Adenovirally Mediated Gene Transfer
To investigate the mechanism of action of AdARKct in
SVGs, VSMCs derived from canine and human saphenous
veins were cultured and infected with AdARKct. Control
preparations consisted of AdGFP-infected and uninfected
cells. Treatment with adenoviral vectors resulted in nearly
100% infection efficiency, as assessed by green fluorescent
protein immunofluorescence (data not shown), which is
consistent with previously published data in cultured
VSMCs and myocytes.15 After AdARKct infection, pro-
tein immunoblotting of whole-cell lysates revealed robust
expression of ARKct (Figure 3, A).
In Vitro Effects of ARKct Inhibition of MAP Kinase
Activation and Cellular Proliferation
To investigate the role of ARKct in mitogenic signaling,
p42/p44 MAP kinase activation was measured in response
to a number of stimuli: LPA, EGF, and serum (FBS). LPA
is a mitogen expressed in serum that has been shown to
activate the ras-MAP kinase pathway exclusively through
G.16 EGF is a tyrosine kinase receptor agonist that stim-
ulates MAP kinase independent of G.17 Figure 3, B,
shows MAP kinase activation, as demonstrated by ERK
phosphorylation, in VSMCs infected with either AdGFP or
AdARKct. Treatment with AdARKct significantly inhib-
ited MAP kinase activity (as evidenced by decreased phos-
phorylated ERK) in response to LPA and serum but not
EGF. These data correlate with similar findings by Iaccarino
and colleagues12 in rat aortic VSMCs, suggesting that MAP
kinase activity in response to serum is mediated primarily
by G.
In vitro proliferative assays were also conducted. First,
tritiated thymidine incorporation in VSMCs was measured
after infection with either AdGFP or AdARKct. As shown
in Figure 3, C, thymidine incorporation after exposure to
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with AdARKct. To confirm these findings, cell counts
were performed on uninfected and AdGFP- or AdARKct-
infected VSMCs treated with or without LPA, EGF, or FBS.
As in the thymidine incorporation experiments, LPA and
FBS induced robust proliferation of uninfected or AdGFP-
infected VSMCs, whereas ARKct expression significantly
inhibited cell proliferation (Figure 3, D). Conversely, EGF-
stimulated cell proliferation was not affected by the pres-
ence of ARKct (Figure 3, D).
TABLE 1. Histologic analysis of POD 90 aortocoronary SV
AdARKct (n  8)
Intimal area (mm2) 1.32 0.44*†
Medial area (mm2) 2.46 0.61
Intima/media ratio 0.59 0.16*†
Maximum wall thickness (mm) 1.14 0.31*†
Minimum wall thickness (mm) 0.59 0.16
Data represented as mean  SEM.
NS, Not significant. Statistical significance determined by analysis of var
between subgroups. *Statistically significant difference between AdAR
between AdARKct- and EV-treated grafts.
The Journal of ThoracicDiscussion
We previously characterized a canine model of aortocoro-
nary SVG IH. By POD 90, histologic analysis revealed that
mean intimal area was approximately 30 times greater in
aortocoronary SVGs than in nongrafted saphenous vein
control preparations.10 Additionally, average medial thick-
ening, intima/media ratio, maximal wall thickness, and min-
imal wall thickness were similarly increased in the SVGs at
POD 90. Although the intimal thickening in this model is
more robust than the average change seen with human
Figure 2. POD 90 angiograms from repre-
sentative animals. A, Control (untreated)
SVG reveals multiple filling defects on an-
giography, suggestive of advanced disease
and IH. B, AdARKct-treated SVG reveals
SVG devoid of significant filling defects on
angiography. POD 90 hematoxylin and eo-
sin-stained slides from representative ani-
mals. Arrows indicate intimal borders. C,
Control (untreated) SVG specimen. D,
AdARKct-treated SVG specimen.
Control (n  7) EV (n  7) P Value
2.83 0.53* 2.41 0.67† .05
2.21 0.70 1.82 0.91 NS
1.22 0.43* 1.47 0.41† .05
1.94 0.90* 1.32 0.44† .05
0.71 0.19 1.32 0.44 NS
with the Newman-Keuls multiple comparison test to identify differences
eated and uninfected (control) SVGs. †Statistically significant differenceGs
iance,
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allel those seen in some patients with early failure of vein
grafts.
In this study, an ex vivo transgene delivery technique
was used. This technique involved adenoviral vectors de-
livered intraluminally at low-distention pressures. Signifi-
cant transgene expression is achieved in the SVG with this
Figure 3. Expression of ARKct inhibits ERK phosphory
vein smooth muscle cells. VSMCs were treated with A
mol/L), EGF (10 mol/L), or FBS (5%) for 5 minutes.
blotted sequentially with antibodies specific for ARKc
protein loading was confirmed with antibody against
experiments. B, Histogram displaying inhibition of LPA
expressing ARKct. Data are expressed as percentage
unstimulated AdGFP-infected control cells (n  4 expe
ARKct versus AdGFP-treated cells when stimulated
untreated, treated with AdARKct, or treated with AdG
for 24 hours; treated with LPA (10 mol/L), EGF (10 
tritiated thymidine. Thymidine incorporation was asses
reported as mean  SEM for n  3 experiments, eac
decreased proliferation versus uninfected and AdGFP
test). D, VSMCs were treated as in A, except cells we
agonists, then trypsinized and counted. Data reported
triplicate. Asterisk indicates P < .001 for decreased pdelivery strategy.10 Furthermore, in this investigation trans-
1688 The Journal of Thoracic and Cardiovascular Surgery ● Decgene expression was not observed in liver and lung speci-
mens from AdARKct-treated animals. This observation
suggests focal, efficient transgene delivery to the SVG. This
result is not unexpected, because adenovirus survival at
room temperature is brief, perhaps as short as 15 minutes.
The transgene delivery method used a 20-minute intralumi-
nal, ex vivo incubation time followed by a heparinized
and VSMC proliferation in isolated canine saphenous
P or AdARKct and then exposed to agonists LPA (10
Green fluorescent protein. A, Lysates were Western
osphorylated ERK (pERK-1/2), and ERK (ERK-1/2). Equal
bulin. Similar results were observed in four different
d FBS-induced ERK phosphorylation in canine VSMCs
ease (mean  SEM) in ERK phosphorylation relative to
nts). Asterisk indicates P < .05 for inhibitory effect of
LPA or FBS (Student t test). C, VSMCs were either
SMCs were then left quiescent in serum-free medium
), and FBS (5%) for 18 hours; and pulse labeled with
y scintillation counting of precipitated DNA. Data are
rformed in triplicate. Asterisk indicates P < .001 for
ed groups (analysis of variance, Bonferroni post hoc
rown 48 hours in serum-free media or in presence of
an  SEM for n  3 experiments, each performed in
ration versus uninfected and AdGFP-treated groups.lation
dGF
GFP,
t, ph
-tu
- an
incr
rime
by
FP. V
mol/L
sed b
h pe
-treat
re g
as me
rolifesaline solution flush. Completion of the aortic and coronary
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before the grafts were perfused. This period at room tem-
perature (approximately 40 minutes) minimized surviving
adenoviral vector and prevented systemic delivery, with
potentially deleterious extragraft expression.
This ex vivo transgene delivery technique is probably
clinically applicable. In this study, subphysiologic disten-
tion pressures were used, the incubation period was limited
to 20 minutes, and the delivery method itself did not appear
to induce any negative effects. Notably, the EV control
grafts (which underwent the delivery process) and the grafts
that received no treatment (no distention) displayed similar
histologic characteristics.
SVGs treated with AdARKct demonstrated an approx-
imately 50% reduction in intimal area relative to grafts
treated with no virus or EV (1.32  0.44 mm2 vs 2.83 
0.53 mm2 vs 2.41  0.67 mm2, P  .05). Differences in
intima/media ratio (0.59  0.16 vs 1.22  0.43 vs 1.47 
0.41, P  .05) and maximal wall thickness (1.14 
0.31 mm vs 1.94  0.90 mm vs 1.87  0.45 mm, P  .05)
were also significant. These findings are interesting because
they demonstrate that the histologic effects of AdARKct
treatment extend well beyond the period of transgene ex-
pression. Indeed, transgene expression with adenoviruses is
typically short-lived, usually lasting between 1 and 3 weeks.
Significant histologic changes were seen on POD 90 in this
study. This suggests that inhibition of early events may be
enough to produce long-term histologic changes. One hy-
pothesis explaining this observation is that inhibition of
VSMC proliferation is required only until the SVG endo-
thelium—which may sustain damage during the harvest and
implantation procedures—can reestablish itself. Once the
endothelium has been reestablished as a complete mono-
layer, VSMCs may be less likely to undergo pathologic
proliferation. Conceivably, then, retreatment with the trans-
gene may not be necessary to achieve continued, beneficial
effects. Importantly, this hypothesis is being investigated by
studying a 1-year time point.
Because of the efficacy of the ARKct transgene in
attenuating the development of IH in vivo, its effect on the
molecular and cellular responses of saphenous vein VSMCs
in vitro was also investigated. It is known that the inhibition
of G signaling can inhibit MAP kinase activation6-7,12 and
thereby effect changes in cell growth and proliferation path-
ways. In this study, the effect of ARKct on the responses
of VSMCs was evaluated in the presence of several well-
known stimulants of cell proliferation: LPA, EGF, and FBS.
LPA has been shown to activate the ras-MAP kinase path-
way exclusively through G,16 whereas EGF is a tyrosine
kinase receptor agonist that stimulates MAP kinase inde-
pendent of G.17 Serum contains a host of other growth
factors and hormones also known to activate G. The
ability of ARKct to attenuate VSMC proliferation in re-
The Journal of Thoracicsponse to both LPA and FBS at a cellular level suggests that
G and MAP kinases play significant roles in the patho-
genesis of IH and provides a potential mechanism for the
observed in vivo effects.
Undoubtedly, multiple biochemical pathways are in-
volved in the pathologic process of IH. Theoretically, dif-
ferent transgenes targeting different pathways could be
combined to act synergistically and thus more effectively
reduce IH. Other potentially important transgenes, such as
nitric oxide synthase, could augment nitric oxide within the
graft and help preserve endothelial function during the
grafting process.18 Tissue inhibitors of metalloproteinase
might also reduce IH by preventing migration of VSMCs.19
Inhibition of phosphatidylinositol 3 kinase signaling by the
tumor suppressor protein PTEN (Phosphate and Tensin
homolog detected on chromosome Ten) has been shown to
inhibit VSMC proliferation and the development of IH.14 It
remains to be determined whether combining these trans-
genes with ARKct might produce a more complete inhi-
bition of SVG IH.
Finally, it is important to recognize that even though
many investigators believe that there is an important
connection between early IH and subsequent graft ath-
erosclerosis and thrombosis, this connection has not been
conclusively proved.20 In other words, it is possible that
IH may be a pathologic entity independent of these two
processes. At POD 90, the major end point of this manu-
script, the incidence of thrombosis is very low and this
study therefore does not help to answer this important
question. Accordingly, ongoing studies examining canine
aortocoronary SVGs 1 year after grafting are being con-
ducted. Such studies may relate early IH to subsequent
SVG failure.
Conclusion
VSMC proliferation and associated IH are early factors
leading to aortocoronary SVG failure. In this study, adeno-
virus-mediated expression of ARKct inhibited aortocoro-
nary SVG IH in a large-animal model. The mechanism for
these changes is not clear but may be through the antipro-
liferative effect of ARKct and inhibition of MAP kinase
signaling, as shown in cultured canine VSMCs. These re-
sults suggest that modulation of the MAP kinase pathway
through ARKct expression may represent a novel therapy
to prevent IH in vascular conduits, including aortocoronary
SVGs.
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